X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATL001 is a clonal neoantigen reactive T cell (cNeT) therapy, which is being evaluated in combination with pembrolizumab for the treatment of advanced unresectable or metastatic non-small cell lung cancer.
Lead Product(s): ATL001,Pembrolizumab
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
cNeT (ATL001) are the active component of the final, precision T cell product which target tumors through recognition of a patient’s clonal neoantigens present on all tumor cells.
Lead Product(s): ATL001,Pembrolizumab
Therapeutic Area: Oncology Product Name: cNet
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
ACE is a proprietary method for determining clonality of patient-specific mutations that drives the PELEUS™ bioinformatics platform. Clonal neoantigens are original mutations formed early in tumor evolution that are expressed on all cancer cells and absent from healthy tissue.
Lead Product(s): Autologous T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 22, 2022
Details:
A positive review by an Independent Data Safety Monitoring Committee, the Company has initiated enrollment in Cohort B of the THETIS clinical trial to evaluate cNeT I(ATL001) in combination with a PD-1 checkpoint inhibitor for the treatment of metastatic malignant melanoma.
Lead Product(s): ATL001,Pembrolizumab
Therapeutic Area: Oncology Product Name: cNet
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
The second GMP manufacturing site will initially support Achilles’ proprietary VELOS™ manufacturing process with an annual capacity of 200 cNeT (Clonal NeoantigenT-cells) doses at peak production. The Company’s first US GMP manufacturing facility to be operated by CBM.
Lead Product(s): ATL001
Therapeutic Area: Oncology Product Name: cNet
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Center for Breakthrough Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 12, 2022
Details:
Secarna will employ its commercially validated discovery and development platform, LNAplus™, to generate ASO candidates against selected targets that potentially play a central role in the ex vivo optimization of personalized T cell therapies being developed by Achilles.
Lead Product(s): Antisense Oligonucleotide
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Secarna Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 10, 2021
Details:
Achilles uses DNA sequencing data from patients, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.
Lead Product(s): Neoantigen Reactive T cells
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2021
Details:
The primary objective of the trial is to assess the safety and tolerability of cNeT. Clinical efficacy will be evaluated as a secondary measure.
Lead Product(s): ATL001
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
Achilles has two ongoing Phase I/IIa trials, including a study of a clonal neoantigen T cell therapy in patients with advanced non-small cell lung cancer, which dosed its first patient in June last year.
Lead Product(s): Neoantigen Reactive T cells
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 06, 2021
Details:
Company's lead drug, ATL001, is a personalised tumour-derived T cell therapy targeting clonal cancer neoantigens. it's lead indications, advanced non-small cell lung cancer and recurrent metastatic melanoma.
Lead Product(s): ATL001
Therapeutic Area: Oncology Product Name: ATL001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 30, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
